Clinical validation of an HPV whole-genome sequencing assay for MRD detection in patients with HPV+ head and neck cancer treated with surgery
Science Translational Medicine · 10.06.2026 · 18 (853)
DOI: 10.1126/scitranslmed.aec1724 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Science Translational Medicine, erschienen am 10.06.2026. Verfasst von Shun Hirayama und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Human Papillomavirus Viruses, Neoplasm, Residual, Papillomavirus Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Institute of Dental and Craniofacial Research.
Abstract (Originalsprache)
Surgery is a standard treatment for early-stage human papillomavirus–associated head and neck cancer (HPV+HNC), yet adjuvant therapy decisions rely on clinicopathologic features with limited prognostic accuracy. Circulating tumor HPV DNA is a promising biomarker, but current assays lack the sensitivity needed for detecting minimal residual disease after surgery. This study evaluated the prognostic value of an HPV whole-genome sequencing assay, HPV-DeepSeek, and compared this with existing methods and clinical standards. One hundred three patients with stage I to IV HPV+HNC treated with surgery were prospectively enrolled (NCT06730412). Blood samples were collected before surgery, postoperatively, and during surveillance and were analyzed using HPV-DeepSeek and droplet digital polymerase chain reaction (PCR) assays. After a median follow-up of 27 months, patients with circulating tumor HPV DNA detected after surgery had worse 2-year disease-free and overall survival than those without detection. Detection after completion of all treatment was also associated with poorer outcomes. Minimal residual disease status was a stronger predictor of recurrence than standard clinicopathologic criteria. Molecular recurrence was identified up to 17.5 months earlier than clinical recurrence and nearly twice as early as with droplet digital PCR. These findings demonstrate that sensitive HPV whole-genome sequencing enables accurate detection of minimal residual disease, early identification of recurrence, and improved postoperative risk stratification, supporting its potential as a tool for guiding personalized adjuvant therapy in HPV+HNC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA 02114, USA.
- Massachusetts Eye and Ear, Boston, MA 02114, USA.
- Department of Otorhinolaryngology-Head and Neck Surgery, Wakayama Medical University, Wakayama 641-8509, Japan.
- Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
- Harvard Medical School, Boston, MA 02115, USA.
ORCID-Profile: Shun Hirayama, Yana Al-Inaya, Michael E Bryan, Dipon Das, Ling Aye, Saskia Naegele, William C Faquin, Peter M Sadow, Matthew G Crowson, Derrick Lin, Allen L Feng, Ross Merkin, Anthony John Iafrate, Lori Wirth, Adam S Fisch, Zoe Guan, Daniel L Faden
Förderung
- National Institute of Dental and Craniofacial Research
Zitieren
APA
Hirayama, S., Al-Inaya, Y., Bryan, M. E., Das, D., Aye, L., Naegele, S., Mendel, J., Faquin, W. C., Sadow, P. M., Crowson, M. G., Lin, D., Varvares, M., Feng, A. L., Deschler, D., Paly, J., Merkin, R., Roberts, T. J., Lawrence, M., Iafrate, A. J., …, & Faden, D. L. (2026). Clinical validation of an HPV whole-genome sequencing assay for MRD detection in patients with HPV+ head and neck cancer treated with surgery. Science Translational Medicine, 18(853). https://doi.org/10.1126/scitranslmed.aec1724
Vancouver
Hirayama S, Al-Inaya Y, Bryan ME, Das D, Aye L, Naegele S, et al. Clinical validation of an HPV whole-genome sequencing assay for MRD detection in patients with HPV+ head and neck cancer treated with surgery. Science Translational Medicine. 2026;18(853). doi:10.1126/scitranslmed.aec1724
BibTeX
@article{Hirayama2026,
author = {Hirayama, Shun and Al-Inaya, Yana and Bryan, Michael E and Das, Dipon and Aye, Ling and Naegele, Saskia and Mendel, Julia and Faquin, William C and Sadow, Peter M and Crowson, Matthew G and Lin, Derrick and Varvares, Mark and Feng, Allen L and Deschler, Daniel and Paly, Jonathan and Merkin, Ross and Roberts, Thomas J and Lawrence, Michael and Iafrate, Anthony John and Wirth, Lori and Fisch, Adam S and Guan, Zoe and Richmon, Jeremy and Faden, Daniel L},
title = {Clinical validation of an HPV whole-genome sequencing assay for MRD detection in patients with HPV+ head and neck cancer treated with surgery},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {853},
doi = {10.1126/scitranslmed.aec1724}
}
EUVIMED